Welcome to Paid Research Studies


Browse Locations ... United States» ... Wyoming» ... Cody






  • Conditions:   Recurrent Non-Small Cell Lung Carcinoma;   Stage IB Non-Small Cell Lung Carcinoma;   Stage IIA Non-Small Cell Lung Carcinoma;   Stage IIB Non-Small Cell Lung Carcinoma;   Stage IIIA Non-Small Cell Lung Cancer
    Interventions:   Drug: Erlotinib Hydrochloride;   Other: Placebo;   Other: Laboratory Biomarker Analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified September 2014

  • Conditions:   Adult Cholangiocarcinoma;   Advanced Adult Hepatocellular Carcinoma;   BCLC Stage C Adult Hepatocellular Carcinoma;   BCLC Stage D Adult Hepatocellular Carcinoma;   Hilar Cholangiocarcinoma;   Localized Non-Resectable Adult Liver Carcinoma;   Recurrent Adult Liver Carcinoma;   Recurrent Childhood Liver Cancer;   Recurrent Extrahepatic Bile Duct Carcinoma;   Recurrent Gallbladder Carcinoma;   Stage II Gallbladder Cancer;   Stage III Childhood Hepatocellular Carcinoma;   Stage IIIA Gallbladder Cancer;   Stage IIIB Gallbladder Cancer;   Stage IV Childhood Hepatocellular Carcinoma;   Stage IV Distal Bile Duct Cancer;   Stage IVA Gallbladder Cancer;   Stage IVB Gallbladder Cancer;   Unresectable Extrahepatic Bile Duct Carcinoma
    Interventions:   Drug: Trametinib;   Drug: Leucovorin Calcium;   Drug: Fluorouracil;   Drug: Capecitabine;   Other: Laboratory Biomarker Analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified January 2015

  • Conditions:   Recurrent Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma
    Interventions:   Biological: Bevacizumab;   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified November 2014

  • Conditions:   Stage I Chronic Lymphocytic Leukemia;   Stage II Chronic Lymphocytic Leukemia;   Stage III Chronic Lymphocytic Leukemia;   Stage IV Chronic Lymphocytic Leukemia
    Interventions:   Drug: Ibrutinib;   Biological: Rituximab;   Drug: Bendamustine Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified December 2014

  • Conditions:   Clear Cell Renal Cell Carcinoma;   Stage III Renal Cell Cancer;   Stage IV Renal Cell Cancer
    Interventions:   Drug: Cabozantinib S-malate;   Drug: Sunitinib Malate;   Other: Laboratory Biomarker Analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified October 2014

  • Conditions:   Adult Acute Megakaryoblastic Leukemia;   Adult Acute Monoblastic Leukemia;   Adult Acute Monocytic Leukemia;   Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11;   Adult Acute Myeloid Leukemia With Maturation;   Adult Acute Myeloid Leukemia With Minimal Differentiation;   Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11;   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1;   Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL;   Adult Acute Myeloid Leukemia Without Maturation;   Adult Acute Myelomonocytic Leukemia;   Adult Erythroleukemia;   Adult Pure Erythroid Leukemia;   Alkylating Agent-Related Acute Myeloid Leukemia;   Secondary Acute Myeloid Leukemia;   Untreated Adult Acute Myeloid Leukemia
    Interventions:   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Idarubicin;   Drug: Vorinostat;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Other: Laboratory Biomarker Analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified September 2014